Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD

https://doi.org/10.17749/2070-4909.2017.10.2.022-030

Full Text:

Abstract

The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial clinical effects, these medications have an impact on COPD treatment costs. Minimizing the costs of highly effective medications is necessary to improve the public medical care and drug supply.

Objective: to identify the key differences between vilantererol / umeclidinum bromide and olodaterol / tiotropium bromide, and evaluate the ways of minimizing health budget expenditures.

Materials and methods. We used the available information from research, clinical trials, and instructions for medical use to conduct a cost analysis that was based on the prices for these medications at different levels of drug supply. As a result, the impact on the healthcare budget was determined under conditions of choosing the least expansive medication and adding vilantererol / umeclidinum bromide in the list of VED.

Results. According to the network meta-analysis, when compared with mono-component drugs, vilantererol / umeclidinum bromide showed a more favorable effect on cardiovascular events, as well as a more pronounced effect on the volume of forced exhalation in the first second (FEV1). For the olodaterol / tiotropium bromide combination, no such trend was seen. The costs of 12-month therapy with vilantererol / umeclidinum bromide and with olodaterol / tiotropium bromide were 27,541 and 36,120 rubles, respectively (a difference of 24%). The average direct medical costs were 32,753 and 41,333 rubles per patient per year, respectively. If the vilantererol / umeclidinum bromide combination is added to the VED list and the manufacturer’s maximum selling price is registered at the level of the reference countries, the savings can reach 3-5%.

Conclusion. In patients with severe and extremely severe COPD, and also when COPD monotherapy in patients without severe symptoms (FEV1 ≥50%, CAT <10 scores, mMRC <2) or with mild to moderate symptoms (FEV1 ≥50%) is not effective, the use of vilantererol / umeclidinum bromide in place of olodaterol / tiotropium bromide is more promising in terms of minimizing health budget spending. 

About the Authors

E. G. Kosolapov
Independent Research Company «Smart Choice»
Russian Federation
Otkrytoe shosse, 23/6, Moscow, 107143


F. S. Kochenkov
Independent Research Company «Smart Choice»
Russian Federation
Otkrytoe shosse, 23/6, Moscow, 107143


N. L. Pogudina
Independent Research Company «Smart Choice»
Russian Federation

PhD, 

Otkrytoe shosse, 23/6, Moscow, 117997



D. V. Blinov
N.I. Pirogov Russian National Research Medical University
Russian Federation

 PhD, 

Ostrovitianova str., 1, Moscow, 117997



N. L. Bondarenko
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation; Clinical Hospital № 85, FMBA of Russia
Russian Federation

PhD, Associate Professor of the Department of Clinical Immunology and Allergology;

Chief Physician,

Kashirskoe shosse, d. 13G, Moscow, 115230



A. V. Karaulov
I.M. Sechenov First Moscow State Medical University, Health Ministry of Russian Federation
Russian Federation

Acad. RAS, Prof., MD, Head of the Department of Clinical Immunology and Allergology, 

ul. Trubetskaya, 8, str. 2, Moscow, 119048



References

1. Federal Clinical Recommendations for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease [Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu khronicheskoi obstruktivnoi bolezni legkikh (in Russian)]. Moscow. 2014; 41 s.

2. Chronic obstructive pulmonary disease. Clinical recommendations [Khronicheskaya obstruktivnaya bolezn’ legkikh. Klinicheskie rekomendatsii (in Russian)]. Moscow. 2016; 69 s.

3. Leshchenko I. V., Avdeev S. N. RMZh. 2016; 16: 1039-1046.

4. Vogelmeier C. F., Criner G. J., Martinez F. J., Anzueto A., Barnes P. J., Bourbeau J. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017; 49 (3).

5. Sulaiman I., Cushen B., Greene G., Seheult J., Seow D., Rawat F. et al. Objective Assessment of Adherence to Inhalers by COPD Patients. Am J Respir Crit Care Med. 2016; DOI:10.1164/rccm.201604-0733OC.

6. Laube B. L., Janssens H. M., de Jongh F. H. C., Devadason S. G., Dhand R., Diot P. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011; 37 (6): 1308-31.

7. Magnussen H., Disse B., Rodriguez-Roisin R., Kirsten A., Watz H., Tetzlaff K., et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014; 371 (14): 1285-94.

8. Singh D., Maleki-Yazdi M. R., Tombs L., Iqbal A., Fahy W. A., Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016; 11: 1413-24.

9. Yang I. A., Clarke M. S., Sim E. H., Fong K. M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2012; (7): CD002991.

10. Crim C., Dransfield M. T., Bourbeau J., Jones P. W., Hanania N. A., Mahler D. A. et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015; 12 (1): 27-34.

11. Roversi S., Corbetta L. Clini E GOLD 2017 recommendations for COPD patients: toward a more personalized approach. COPD Research and Practice. 2017; 3 (5).

12. Barnes PJ. Gold 2017: a new report. Chest. 2017; 151 (2): 245-246.

13. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. URL: http://goldcopd.org. Accessed: 17.03.2017.

14. Ninane V., Vandevoorde J., Cataldo D. et al. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences. Respir Med. 2015 Nov; 109 (11): 1430-8.

15. Anoro Ellipta. Instructions for medical use. State Drug Register [Instruktsiya po meditsinskomu primeneniyu. Gosudarstvennyi reestr Lekarstvennykh Sredstv (in Russian)]. URL: www.grls.rosminzdrav.ru. Accessed: 15.12.2016.

16. Spiolto Respimat. Instruktsiya po meditsinskomu primeneniyu. Gosudarstvennyi reestr Lekarstvennykh Sredstv. [Instruktsiya po meditsinskomu primeneniyu. Gosudarstvennyi reestr Lekarstvennykh Sredstv (in Russian)]. URL: www.grls.rosminzdrav.ru. Accessed: 15.12.2016.

17. Bouyssou T., Casarosa P., Naline E., Pestel S., Konetzki I., Devillier P. et al. Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010; 334: 53-62.

18. Slack R. J., Barrett V. J., Morrison V. S. et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013; 344 (1): 218-30.

19. Schlueter M., Gonzalez-Rojas N., Baldwin M. et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016 Apr; 10 (2): 89-104.

20. Calzetta L., Rogliani P., Matera M. G., Cazzola M. A. Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016 May; 149 (5): 1181-96.

21. Horita N., Goto A., Shibata Y., Ota E., Nakashima K., Nagai K., Kaneko T. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews. 2017; 2. Art. No.: CD012066.

22. Calzetta L., Rogliani P., Ora J. et al. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017; 26: 160043.

23. Price D., Østrem A., Thomas M., Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review. Int J Chron Obstruct Pulmon Dis. 2016 Dec 30; 12: 141-168.

24. Donohue J. F., Betts K. A., Xiaoyan Du. E. et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017; 12: 367-381.

25. Feldman G., Maltais F., Khindri S. et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016 Apr 7; 11: 719-30.

26. Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014; 2 (6): 472-486.


For citation:


Kosolapov E.G., Kochenkov F.S., Pogudina N.L., Blinov D.V., Bondarenko N.L., Karaulov A.V. COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2017;10(2):22-30. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.2.022-030

Views: 333


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)